Cargando…
The Thyroid Pathologist Meets Therapeutic Pharmacology
The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug c...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890439/ https://www.ncbi.nlm.nih.gov/pubmed/36723855 http://dx.doi.org/10.1007/s12022-023-09749-1 |
_version_ | 1784880947328450560 |
---|---|
author | Sande, Christopher M. Tondi Resta, Isabella Livolsi, Virginia A. |
author_facet | Sande, Christopher M. Tondi Resta, Isabella Livolsi, Virginia A. |
author_sort | Sande, Christopher M. |
collection | PubMed |
description | The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug classes for the thyroid pathologist: iodine, antithyroid drugs, psychotropic drugs, antibiotics, cardiotropic drugs, antidiabetic drugs, and immunomodulatory agents. Radioactive iodine initially induces mild histologic changes; however, the long-term effects include marked follicular atrophy, fibrosis, and nuclear atypia—changes that vary depending on the pre-therapy condition of the gland. Some psychotropic drugs have been associated with a spectrum of inflammatory changes throughout the gland. The tetracycline class of antibiotics, namely minocycline, can lead to a grossly black thyroid gland with pigment seen in both colloid and follicular epithelial cells while variably present within thyroid nodules. The surgical pathologist most commonly sees an amiodarone-affected gland removed for hyperthyroidism, and the histologic findings again depend on the pre-therapy condition of the gland. While GLP-1 receptor agonists carry an FDA black box warning for patients with a personal or family history of multiple endocrine neoplasia or medullary thyroid carcinoma, the C cell hyperplasia originally noted in rats has not borne out in human studies. Finally, thyroiditis and hypothyroidism are well known complications of checkpoint inhibitor therapy, and rare cases of severe thyroiditis requiring urgent thyroidectomy have been reported with unique histologic findings. In this review, we describe the histologic findings for these drugs and more, in many cases including their functional consequences. |
format | Online Article Text |
id | pubmed-9890439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-98904392023-02-01 The Thyroid Pathologist Meets Therapeutic Pharmacology Sande, Christopher M. Tondi Resta, Isabella Livolsi, Virginia A. Endocr Pathol Article The effects of many pharmacological agents on thyroid function are well known. Direct influences on measurements of thyroid function tests are also described. However, certain classes of drugs produce morphological changes in the gland. This review focuses on the significance of the following drug classes for the thyroid pathologist: iodine, antithyroid drugs, psychotropic drugs, antibiotics, cardiotropic drugs, antidiabetic drugs, and immunomodulatory agents. Radioactive iodine initially induces mild histologic changes; however, the long-term effects include marked follicular atrophy, fibrosis, and nuclear atypia—changes that vary depending on the pre-therapy condition of the gland. Some psychotropic drugs have been associated with a spectrum of inflammatory changes throughout the gland. The tetracycline class of antibiotics, namely minocycline, can lead to a grossly black thyroid gland with pigment seen in both colloid and follicular epithelial cells while variably present within thyroid nodules. The surgical pathologist most commonly sees an amiodarone-affected gland removed for hyperthyroidism, and the histologic findings again depend on the pre-therapy condition of the gland. While GLP-1 receptor agonists carry an FDA black box warning for patients with a personal or family history of multiple endocrine neoplasia or medullary thyroid carcinoma, the C cell hyperplasia originally noted in rats has not borne out in human studies. Finally, thyroiditis and hypothyroidism are well known complications of checkpoint inhibitor therapy, and rare cases of severe thyroiditis requiring urgent thyroidectomy have been reported with unique histologic findings. In this review, we describe the histologic findings for these drugs and more, in many cases including their functional consequences. Springer US 2023-02-01 2023 /pmc/articles/PMC9890439/ /pubmed/36723855 http://dx.doi.org/10.1007/s12022-023-09749-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Sande, Christopher M. Tondi Resta, Isabella Livolsi, Virginia A. The Thyroid Pathologist Meets Therapeutic Pharmacology |
title | The Thyroid Pathologist Meets Therapeutic Pharmacology |
title_full | The Thyroid Pathologist Meets Therapeutic Pharmacology |
title_fullStr | The Thyroid Pathologist Meets Therapeutic Pharmacology |
title_full_unstemmed | The Thyroid Pathologist Meets Therapeutic Pharmacology |
title_short | The Thyroid Pathologist Meets Therapeutic Pharmacology |
title_sort | thyroid pathologist meets therapeutic pharmacology |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890439/ https://www.ncbi.nlm.nih.gov/pubmed/36723855 http://dx.doi.org/10.1007/s12022-023-09749-1 |
work_keys_str_mv | AT sandechristopherm thethyroidpathologistmeetstherapeuticpharmacology AT tondirestaisabella thethyroidpathologistmeetstherapeuticpharmacology AT livolsivirginiaa thethyroidpathologistmeetstherapeuticpharmacology AT sandechristopherm thyroidpathologistmeetstherapeuticpharmacology AT tondirestaisabella thyroidpathologistmeetstherapeuticpharmacology AT livolsivirginiaa thyroidpathologistmeetstherapeuticpharmacology |